Neuphoria Therapeutics
NEUP
7 hedge funds and large institutions have $935K invested in Neuphoria Therapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 4 closing their positions.
242% more capital invested
Capital invested by funds: $273K → $935K (+$662K)
9.28% more ownership
Funds ownership: 0% → 9.28% (+9.3%)
13% less funds holding
Funds holding: 8 → 7 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$326K |
| 2 |
PWM
Prosperity Wealth Management
San Ramon,
California
|
+$127K |
| 3 |
CWP
Cyndeo Wealth Partners
St. Petersburg,
Florida
|
+$46.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$45.7K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$22.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$10.2K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$3.23K |
NEUP Hedge Fund Activity: Q1 2025 in Review
7 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q1 2025, worth a combined $935K — up 242% from $273K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of NEUP and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was AdvisorShares Investments, opening a new position worth an estimated $326K. The largest seller was Jane Street, exiting entirely with an estimated $45.7K sold.
- 7 institutional investors held Neuphoria Therapeutics (NEUP) as of Q1 2025, down from 8 in Q4 2024.
- Funds reported $935K of Neuphoria Therapeutics stock for Q1 2025, up 242% quarter-over-quarter.
- 3 funds opened new Neuphoria Therapeutics positions in Q1 2025 and 4 closed out, a net change of -1 holder.
- The largest Neuphoria Therapeutics buyer in Q1 2025 was AdvisorShares Investments, an estimated $326K added.
- The largest Neuphoria Therapeutics seller in Q1 2025 was Jane Street, an estimated $45.7K sold.
Based on aggregated 13F filings for Q1 2025.